Global Alzheimer’s Platform Foundation Collaborates on First-Ever Performance Recommendations for Blood-Based Biomarker Tests

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]

Read more »

Investors Meet Opportunity at Inaugural Global Alzheimer’s Platform Foundation Innovation Summit

At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]

Read more »

A Meeting of the Minds

For the first time in 15 years, there are new Alzheimer’s drug treatments on the horizon that are expected to seek regulatory approval by the FDA and leading experts are increasely optimistic that a major breakthrough in Alzheimer’s research will occur within the next five years. We are at a moment of peak opportunity – […]

Read more »
To top